Elsevier

The Surgeon

Volume 7, Issue 3, June 2009, Pages 174-180
The Surgeon

COX-2, VEGF and tumour angiogenesis

https://doi.org/10.1016/S1479-666X(09)80042-5Get rights and content

Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target. Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells. While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.

References (71)

  • FM Giardiello et al.

    Prostanoids, ornithine decarboxylase and polyamines in primary prevention of familial adenomatous polyposis

    Gastroenterol

    (2004)
  • NM Pandya et al.

    Angiogenesis — A new target for future therapy

    Vascular Pharmacol

    (2006)
  • M Tsujii et al.

    Cyclooxygenase regulates angiogenesis induced by colon cancer cells

    Cell

    (1998)
  • D Nie et al.

    Thromboxane A2 regulation of endothelial cell migration, angiogenesis and tumour metastasis

    Biochem Biophys Res Commun

    (2000)
  • G Eibl et al.

    PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells

    Biochem Biophys Res Commun

    (2003)
  • FG Buchanan et al.

    Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor

    Gastroenterol

    (2004)
  • Y-L Wu et al.

    Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts

    Biomed Pharm

    (2005)
  • P-E Neagoe et al.

    Vascular endothelial growth factor (VEGF) — A156 induced prostacyclin synthesis requries the activation of VEGF receptor-1 and -2 heterodimer

    J Biol Chem

    (2005)
  • Cancer in Ireland 1994–2005

  • JF Murphy et al.

    Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependant proliferation of endothelial cells (EC) via the VEGF-2 receptor

    Faseb J

    (2001)
  • BH von Rahden et al.

    Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma

    Cancer Res

    (2005)
  • KM Sheehan et al.

    The relationship between cyclooxygenase-2 expression and colorectal cancer

    JAMA

    (1999)
  • G Meisenberg et al.
  • AJ Dannenberg et al.

    Cyclo-oxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

    J Clin Oncol

    (2005)
  • JA Baron et al.

    Nonsteroidal anti-inflammatory drugs and cancer prevention

    Ann Review Med

    (2000)
  • LAG Rodriguiz et al.

    Reduced risk of colorectal cancer among long term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs

    Epidemiology

    (2001)
  • M Thun et al.

    Aspirin use and risk of fatal cancer

    Cancer Res

    (1993)
  • KE Anderson et al.

    Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer

    J Natl Cancer Inst

    (2002)
  • D Wang et al.

    Prostaglandins and cancer

    Gut

    (2006)
  • JL Masferrer et al.

    Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors

    Cancer Res

    (2000)
  • R Masunaga et al.

    Cyclooxygenase-2 expression correlates with tumour neovascu-larization and prognosis in human colorectal carcinoma patients

    Clin Cancer Res

    (2000)
  • ON Tucker et al.

    Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer

    Cancer Res

    (1999)
  • MT Yip-Schneider et al.

    Cyclooxygenase-2 expression in human pancreatic adenocarcinomas

    Carcinogenesis

    (2000)
  • A Kokawa et al.

    Increased expression of cyclooxygenase-2 in human pancreatic neoplasia and potential for chemoprevention by cyclooxygenase inhibitors

    Cancer

    (2001)
  • MA Molina et al.

    Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by non steroidal anti-inflammatory drugs

    Cancer Res

    (1999)
  • Cited by (102)

    • A review of HER2 overexpression and somatic mutations in cancers

      2023, Critical Reviews in Oncology/Hematology
    • The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2

      2020, Prostaglandins and Other Lipid Mediators
      Citation Excerpt :

      Modalities that reduce normal tissue radiosensitivity and/or increase tumour radioresponsiveness are of great interest clinically. The preferential expression of cyclooxygenase (COX)-2 in tumours versus normal tissues makes it a bona fide pharmacological target for anti-cancer treatment [4]. COX is the enzyme responsible for the conversion of arachidonic acid to prostaglandins.

    • COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models

      2018, Biomaterials
      Citation Excerpt :

      It plays a critical role in initiation and resolution of inflammation [9]. Enhanced COX-2 expression in different cancer types resulted in elevated levels of proangiogenic factors, like VEGF, leading to tumor progression through elevated angiogenesis [10,11]. Additionally, increased level of COX-2 derived PEG2 can stimulate tumor cell proliferation, motility while inhibiting apoptosis through several tumor-permissive factors like increased angiogenesis and impaired immunosurveillance [12].

    View all citing articles on Scopus
    View full text